OGEN News and Press, Oragenics Inc. From 03/21/19

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced the pricing of its previously announced underwritten public offering of 16,666,668 shares of common stock, short-term...

Oragenics (NYSEMKT: OGEN ) has slipped 13.1% after announcing a proposed equity offering . More news on: Oragenics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that it has commenced a proposed underwritten public offering of common stock of the Company, together with warrants ...

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publication of a preclinical study using the lead compound from its lantibiotics program, OG...

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), announced today that Alan Joslyn, Ph.D., president and CEO of Oragenics will be a featured presenter at NobleCon1...